- Home
- GLXG vs NRSN Comparison
GLXG vs NRSN Comparison
Compare GLXG & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- NRSN
- Stock Information
- Founded
- GLXG 2013
- NRSN 2017
- Country
- GLXG Hong Kong
- NRSN Israel
- Employees
- GLXG N/A
- NRSN N/A
- Industry
- GLXG
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- GLXG
- NRSN Health Care
- Exchange
- GLXG NYSE
- NRSN Nasdaq
- Market Cap
- GLXG 17.7M
- NRSN 17.8M
- IPO Year
- GLXG 2024
- NRSN 2021
- Fundamental
- Price
- GLXG $0.98
- NRSN $1.18
- Analyst Decision
- GLXG
- NRSN Hold
- Analyst Count
- GLXG 0
- NRSN 1
- Target Price
- GLXG N/A
- NRSN N/A
- AVG Volume (30 Days)
- GLXG 3.3M
- NRSN 169.1K
- Earning Date
- GLXG 02-16-2025
- NRSN 12-18-2024
- Dividend Yield
- GLXG N/A
- NRSN N/A
- EPS Growth
- GLXG N/A
- NRSN N/A
- EPS
- GLXG 0.04
- NRSN N/A
- Revenue
- GLXG $3,858,088.00
- NRSN N/A
- Revenue This Year
- GLXG N/A
- NRSN N/A
- Revenue Next Year
- GLXG N/A
- NRSN N/A
- P/E Ratio
- GLXG $22.24
- NRSN N/A
- Revenue Growth
- GLXG N/A
- NRSN N/A
- 52 Week Low
- GLXG $0.70
- NRSN $0.51
- 52 Week High
- GLXG $16.93
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- NRSN 55.53
- Support Level
- GLXG N/A
- NRSN $1.01
- Resistance Level
- GLXG N/A
- NRSN $1.20
- Average True Range (ATR)
- GLXG 0.00
- NRSN 0.08
- MACD
- GLXG 0.00
- NRSN 0.01
- Stochastic Oscillator
- GLXG 0.00
- NRSN 81.58
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.